I always hesitate to amplify something I disagree with, but this flavor of messaging is extremely counterproductive. We're talking about cerebral venous sinus thrombosis specifically; claiming an apples-to-apples comparison to less serious VTE like DVT only erodes public trust.
https://twitter.com/angie_rasmussen/status/1381967413944623109
Does the incidence of CSVT after J&J vaccine still seem much, much lower than the incidence of CSVT in women taking OCPs? Yes: 1 in 1,000,000 vs 1 in ~37,000. ncbi.nlm.nih.gov/pmc/articles/P…
I know of no reliable evidence with which to estimate the risk of CSVT with COVID. This is the largest analysis I've found this morning, which described... 8 patients with CSVT. sciencedirect.com/science/articl…
I don't say this to downplay the risks of COVID, which are numerous, varied and significant. But venous sinus thrombosis specifically is just one about which we have a paucity of data. It's facially false to say it happens to 1 in 5 patients with COVID.
https://twitter.com/WF_Parker/status/1381964974063550464
As is so often the case, I think @AlexJohnLondon may have said it best.
https://twitter.com/AlexJohnLondon/status/1381969503748292609
@AlexJohnLondon Finally, to at least attempt to be really clear, this argument is agnostic of whether the pause is warranted or not. We should be careful in our #SciComm regardless of our stance on that issue.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
